CTxONE plays a role in a number of research collaborations. The following projects are included in the CTxONE portfolio:

Chromatin modifying enzymes

Description: Two pre-clinical cancer programs which target proteins that drive the development of solid and blood-borne cancers
Status: Partnered with Pfizer Inc.

First-in-class KAT6A/KAT6B Inhibitor CTx-648 (PF-9363) Demonstrates Potent Anti-tumor Activity in ER+ Breast Cancer with KAT6A Dysregulation (Abstract 1130) AACR 2021


Description: PRMT5 inhibitor for the treatment of blood disorders and haematological and solid tumours
Status: Partnered with Cancer Research Technology UK